NASDAQ:INHX - Inhibitex Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inhibitex logoInhibitex, Inc. develops antibody-based products for the treatment and prevention of bacterial and fungal infections. The Company produces products that can be used as vaccines, binding inhibitors or separation supports for affinity purifications. The Company's lead product candidate, Veronate, which entered into Phase III clinical trial in the second half of 2004, is being developed for the prevention of hospital-associated infections in premature, very low birth weight, (VLBW) infants.

Receive INHX News and Ratings via Email

Sign-up to receive the latest news and ratings for INHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:INHX
CUSIPN/A
Phone+1-678-7461100

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

Inhibitex (NASDAQ:INHX) Frequently Asked Questions

What is Inhibitex's stock symbol?

Inhibitex trades on the NASDAQ under the ticker symbol "INHX."

Has Inhibitex been receiving favorable news coverage?

Media coverage about INHX stock has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inhibitex earned a news and rumor sentiment score of 0.16 on Accern's scale. They also gave news articles about the healthcare company an impact score of 47.89 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Inhibitex.

How do I buy shares of Inhibitex?

Shares of INHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Inhibitex?

Inhibitex's mailing address is 9005 Westside Pkwy, ALPHARETTA, GA 30009-4783, United States. The healthcare company can be reached via phone at +1-678-7461100.


MarketBeat Community Rating for Inhibitex (NASDAQ INHX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  191
MarketBeat's community ratings are surveys of what our community members think about Inhibitex and other stocks. Vote "Outperform" if you believe INHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel